scholarly journals Age of Onset and Clinical Signs in Canine Atopic Dermatitis

2012 ◽  
Vol 16 (2) ◽  
pp. 126-134
Author(s):  
Nobuaki ARAI ◽  
Shiho USUI ◽  
Yuzo KOKETSU
2021 ◽  
Vol 8 ◽  
Author(s):  
Ju-Yong Park ◽  
Seon-Myeong Kim ◽  
Jung-Hyun Kim

The management of canine atopic dermatitis, an allergic skin disorder, is challenging. To investigate the effect of phototherapy using a 308-nm excimer light as a topical treatment for canine atopic dermatitis, 10 dogs with canine atopic dermatitis and 10 with non-allergic skin were enrolled in this study. Phototherapy was applied every 7 days for a total of 2 months. The skin microbiome, skin barrier function, and clinical outcomes were evaluated after phototherapy. Phototherapy significantly changed the composition of the skin microbiome of dogs with atopic dermatitis and significantly increased the relative abundance of the phyla Actinobacteria and Cyanobacteria. It significantly alleviated the clinical signs of canine atopic dermatitis without serious adverse effects. Transepidermal water loss, as a measure of skin barrier function, significantly decreased after phototherapy. In addition, phototherapy increased microbial diversity and decreased the relative abundance of Staphylococcus pseudintermedius associated with the severity of canine atopic dermatitis. These results suggest that the excimer light therapy is a suitable and safe therapeutic option for canine atopic dermatitis, which is also a spontaneous animal model of atopic dermatitis.


2006 ◽  
Vol 54 (3) ◽  
pp. 353-366 ◽  
Author(s):  
Noémi Tarpataki ◽  
Kinga Pápa ◽  
J. Reiczigel ◽  
P. Vajdovich ◽  
K. Vörös

Medical records of 600 dogs diagnosed with atopic dermatitis were reviewed and evaluated with reference to history, geographical distribution, breed predilection, clinical signs and positive reactions to allergens as determined by intradermal skin testing (IDT) manufactured by Artuvetrin Laboratories**. In 66.6% of dogs, the age of onset of atopic dermatitis was between 4 months and 3 years. Dogs living in the garden suburb of Budapest were more sensitive to house dust mites, fleas and moulds, and dogs from the western part of Hungary were more sensitive to weeds than to other allergens (p < 0.01). Positive reactions were most common to Dermatophagoides farinae followed by human dander. The breed distribution found in the present study was consistent with that reported in the literature, except for the breeds Hungarian Vizsla, Pumi, French bulldog, Doberman Pinscher and Bobtail which were over-represented among atopic dogs compared to the breed distribution of the general dog population of a large city in Hungary. Breeds with verified adverse reaction to food were Cocker spaniels, French bulldogs, Bullmastiffs, Bull terriers, St. Bernards, Tervurens, West Highland White terriers and American Staffordshire terriers (p < 0.05). The clinical signs of atopic dermatitis and their occurrence are in accordance with the data described in the literature.


2014 ◽  
Vol 175 (22) ◽  
pp. 560-560 ◽  
Author(s):  
A. Plevnik Kapun ◽  
J. Salobir ◽  
A. Levart ◽  
G. Tav ar Kalcher ◽  
A. Nemec Svete ◽  
...  

2018 ◽  
Vol 182 (14) ◽  
pp. 406-406 ◽  
Author(s):  
Christoph J Klinger ◽  
Stefan Hobi ◽  
Cornelia Johansen ◽  
Hans-Joachim Koch ◽  
Karin Weber ◽  
...  

Atopic dermatitis (AD) in dogs is among the most common skin diseases in small animal practice. It is an inflammatory disease based on a genetic predisposition to develop hypersensitivity against environmental and food allergens and typical clinical signs up exposure. Treatment sometimes can be difficult and associated with adverse effects. Previous studies evaluating cholecalciferol as treatment for human AD have shown promising results. With canine AD being a good animal model for its human counterpart, it was hypothesised that cholecalciferol might have beneficial clinical effects in dogs, too. In this randomised, placebo-controlled, double-blinded eight-week cross-over study, 23 client-owned dogs received either systemic cholecalciferol (n=16), a vitamin D receptor analogue (n=8) or placebo (n=13). Blood samples for ionised calcium were obtained regularly during the study, and Canine Atopic Dermatitis Extent and Severity Index and pruritus scores, blood levels of vitamin D metabolites, measurements of skin pH and transepidermal water loss were determined before and after. Pruritus and lesion scores decreased significantly in the cholecalciferol group versus placebo. No differences in water loss or skin pH were observed. An increase in serum 25-hydroxycholecalciferol strongly correlated with a reduction in pruritus. Systemic cholecalciferol may be a viable treatment option for canine AD.


2012 ◽  
Vol 57 (No. 8) ◽  
pp. 410-419 ◽  
Author(s):  
G. Zur ◽  
I. Skorinsky ◽  
T. Bdolah-Abram

&nbsp; The aim of the study was to examine for the first time the various aspects of canine atopic dermatitis (CAD) presenting in a Middle Eastern country. Medical records of 164 dogs diagnosed with CAD were evaluated. Associations between signalment, lifestyle, clinical signs and allergens were evaluated statistically. Labrador Retriever, German Shepherd dog, Boxer, French Bulldog, Golden Retriever and Shar-Pei breeds were presented more frequently than the regular hospital population (P &lt; 0.0001), and had an earlier disease onset time (P &lt; 0.01). In 22 dogs (13%) signs of CAD were noticed at less than six months of age. Most dogs (75%) lived indoors. Most dogs (83%) had lesions on the ventral part of the body and 68% had foot lesions. After excluding flea allergy dermatitis by implementing strict flea control, 60% of the dogs presented with dorsal distribution of skin lesions. Dogs with ventral lesions were younger when clinical signs first appeared (P &lt; 0.05). Most of the dogs were allergic to dust and/or dust mites (75.6%), with weeds and trees as the next most common allergens. CAD is similar worldwide, but geographic differences may be attributable to genetic pools and allergen loading. This study also shows that early onset of clinical signs, especially in breeds predisposed to CAD and with a dorsal distribution of skin lesions, should not rule out the diagnosis of CAD. &nbsp;


2018 ◽  
Vol 49 (1) ◽  
pp. 16
Author(s):  
M. N. SARIDOMICHELAKIS (Μ. Ν. ΣΑΡΙΔΟΜΙΧΕΛΑΚΗΣ) ◽  
A. F. KOUTINAS (Α.Φ. ΚΟΥΤΙΝΑΣ)

Canine atopic dermatitis is a common clinical entity, characterized by pruritus due to sensitization against common enviromental allergens. It has been proven that there is strong breed predisposition. Genetically programmed dogs overproduct reaginic antibodies (IgE and/or IgGd) after their exposure to airborne allergens (dust mites, epithelia, pollens and molds) which consequently fix themselves to the mast cells of the skin. After reexposure to the same allergens these cells degranulate, with subsequent release of many pharmacologically active substances (histamine, leucotrienes, Prostaglandines etc). However, this is a rather simplistic explanation; the true pathogenesis of atopy is more complicated and still not well understood. Clinical signs first appear between 6 months and 3 years of age. Pruritus, the mainstay of atopy, can be seasonal or perennial. Skin lesions, appearing in later, are attributed to pruritus and/or to secondary complications (staphylococcal pyoderma, seborrhea, dry skin, Malassezia dermatitis). The diagnosis, based on history and clinical findings, necessitates exclusion of other pruritic skin diseases and identification of the offending allergens by using the intradermal test and/or serology (ELISA, RAST). The latter method is diagnostically inferior to intradermal skin test due to the high rate of false positive reactions. Therapeutic options include avoidance of the allergens responsible for sensitization, systemic therapy with glucocorticoids, antihistamines and essential fatty acids in various combinations, topical antipruritic therapy, hyposensitization which is the best therapeutical modality for the perennial form of the disease and management of secondary complications as well as of other concurrent allergic skin diseases, such as food and flea allergy.


2018 ◽  
Vol 183 (21) ◽  
pp. 654-654 ◽  
Author(s):  
Antonio José Villatoro ◽  
Manuel Hermida-Prieto ◽  
Viviana Fernández ◽  
Fernando Fariñas ◽  
Cristina Alcoholado ◽  
...  

Canine atopic dermatitis (AD) is a common skin disease with a 10–15 per cent prevalence. Current treatments vary in their efficacy and safety. The immunomodulatory properties of mesenchymal stem cells (MSCs) make them a promising alternative treatment. The aim of this study was to evaluate the therapeutic efficacy and safety of allogeneic canine adipose MSCs (cAd-MSCs) in dogs with refractory AD. Twenty-six dogs, suffering from AD for at least 12 months, not responding to conventional therapy, received an intravenous dose of 1.5×106 cAd-MSCs/kg bodyweight. Clinical signs, haematological and biochemistry profiles, and AD severity were assessed in a six-month follow-up using a validated scoring system (Canine Atopic Dermatitis Extent and Severity Index, version 4 (CADESI-04)). The degree of pruritus was quantified using a validated visual analogue scale, and also owner’s global assessment of treatment efficacy. Twenty-two animals completed the study. Pruritus and CADESI-04 scores decreased significantly after one week or month of treatment, respectively, and remained stable for six months. Owner’s global assessment score was 2.15±1.15 for all the animals in the study. In conclusion, systemic administration of allogeneic cAd-MSCs appeared to be a simple therapy with positive outcome in the remission of clinical signs for AD refractory to conventional medications, for at least six months and with no adverse events.


Sign in / Sign up

Export Citation Format

Share Document